Studies have shown that the first treatment you receive for cancer is by far the most important. On average, multiple myeloma patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere.
SCCA provides superior, leading-edge treatment for people diagnosed with multiple myeloma, a form of cancer that affects white blood cells called plasma cells.
Request an appointment
Why choose SCCA?
A national leader in cancer care
SCCA is the leading cancer treatment center in the region and among the top nationally, according to U.S. News & World Report.
NCI comprehensive cancer center
We are a comprehensive cancer center, a designation from the National Cancer Institute that reflects our scientific leadership and the depth and breadth of our research to prevent, diagnose and treat cancer.
Ranked among the best transplant centers in the nation
- Ours is one of only 5 out of 179 transplant centers nationwide whose patients achieved higher-than-expected survival rates for the last four consecutive years, according to a study by the Center for International Blood and Marrow Transplant Research
- SCCA is the leading cancer treatment center in the region and among the top five nationally, according to U.S. News & World Report.
SCCA was formed, in part, to bring promising new cancer treatments to patients faster. This means that people who have multiple myeloma will find more treatment options at SCCA than might be found elsewhere. Many or our patients receive such therapies through clinical research studies conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine. The doctors here are world leaders in research and working to better understand the causes of multiple myeloma and provide effective treatments.